In this proof-of-concept study, bedaquiline therapy cleared Mycobacterium leprae by four weeks of treatment in patients with ...

Antengene’s new drug application (NDA) for Xpovio (selinexor) has gained approval from the Indonesia National Agency of Drug ...

A phase 1/2 trial is evaluating HLD-0915, a novel oral therapy, for metastatic castration-resistant prostate cancer in up to ...

For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy is associated with lower ...

Receiving Fast Track designation for PYX-201 from the FDA marks a significant milestone for Pyxis Oncology, recognizing our potential to address the significant medical need in R/M HNSCC. This ...

Pyxis Oncology (PYXS) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PYX-201 for the treatment of ...

Charles Psychiatric Associates. "Now that it is also available as a monotherapy, healthcare providers have the freedom to further personalize treatment plans based on individual needs," Mattingly ...

Cancer-control outcomes of metastatic castration resistant prostate cancer patients with BRCA-gene or tumor suppressor mutations undergoing 177-lutetium PSMA radioligand therapy.

Cardiovascular mortality risk in primary penile cancer patients: A retrospective cohort study from 2000 to 2021. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium.

Two PYX-201 trials are now actively recruiting and are designed to evaluate PYX-201 as monotherapy in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC ...

Detailed price information for Pyxis Oncology Inc (PYXS-Q) from The Globe and Mail including charting and trades.